1. Home
  2. EMF vs BNR Comparison

EMF vs BNR Comparison

Compare EMF & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Templeton Emerging Markets Fund

EMF

Templeton Emerging Markets Fund

HOLD

Current Price

$19.93

Market Cap

253.7M

Sector

Finance

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$20.83

Market Cap

252.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EMF
BNR
Founded
1987
2014
Country
United States
China
Employees
N/A
N/A
Industry
Finance/Investors Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.7M
252.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
EMF
BNR
Price
$19.93
$20.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
42.2K
27.4K
Earning Date
01-01-0001
06-05-2026
Dividend Yield
6.16%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.58
$2.18
52 Week High
$21.20
$41.72

Technical Indicators

Market Signals
Indicator
EMF
BNR
Relative Strength Index (RSI) 64.16 51.77
Support Level $16.24 $19.72
Resistance Level $20.44 $23.19
Average True Range (ATR) 0.43 1.44
MACD 0.18 0.55
Stochastic Oscillator 91.97 67.75

Price Performance

Historical Comparison
EMF
BNR

About EMF Templeton Emerging Markets Fund

Templeton Emerging Markets Fund is a closed-end management investment company that seeks long-term capital appreciation by investing mainly in emerging country equity securities under normal market conditions. It invests across various sectors, including Pharmaceuticals, Beverages, Broadline Retail, Metals & Mining, Banks, Food Products, Semiconductors & Semiconductor Equipment, Insurance, Entertainment, and others.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: